Efforts to diagnose and manage AD earlier in its disease course have centered on the identification of biomarkers24—measures shown to correlate with disease course, but without establishment in AD’s pathological underpinnings of misfolded proteins (tau tangles and amyloid-beta (Aβ) plaques)25–27. This evidence concerns the gene MAPT and Alzheimer disease.